医学
内科学
肾细胞癌
胃肠病学
乳头状肾细胞癌
皮疹
肾癌
肿瘤科
无进展生存期
肾透明细胞癌
埃罗替尼
癌症
化疗
表皮生长因子受体
作者
Ramaprasad Srinivasan,Sandeep Gurram,Eric A. Singer,Abhinav Sidana,Munjid Al Harthy,Mark W. Ball,Julia C. Friend,Lisa Mac,Erin B. Purcell,Cathy D. Vocke,Christopher J. Ricketts,Heidi H. Kong,Edward W. Cowen,Ashkan A. Malayeri,Joanna H. Shih,Maria J. Merino,W. Marston Linehan
标识
DOI：10.1056/nejmoa2200900
摘要
The combination of bevacizumab and erlotinib showed antitumor activity in patients with HLRCC-associated or sporadic papillary renal-cell carcinoma. Toxic effects were those known to be associated with this combination. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT01130519.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
cdercder
GingerF
Kao
柚子茶
掐钰
zjh33
Nole
Criminology34
Wells
秋风
无极微光
aajhajkahna
DW
Sapphire
dew
学术文献互助
Loscipy
YifanWang
Syening
Anonymous
皖公网安备34019202002308
